Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Review Article

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects

Author(s): Katharine Hodel, Ananda Fonseca, Islania Barbosa, Caio Medina, Brenda Alves, Carine Maciel, Daniel Nascimento, Gessualdo Oliveira-Junior, Lorena Pedreira, Monielly de Souza and Ana Leonor Godoy*

Volume 25, Issue 13, 2024

Published on: 22 January, 2024

Page: [1651 - 1663] Pages: 13

DOI: 10.2174/0113892010264503231108070917

Price: $65

conference banner
Abstract

Important physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the prevalence, severity, and lethality of the disease. Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin. Similarly, these differences between healthy people and obese people can be correlated to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the absorption and distribution of the vaccine that will be lower than desired or can be linked to the inflammatory state in obese patients, which can influence the humoral immune response. Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.

Keywords: Pharmacokinetics, obesity, safety, COVID-19, SARS-CoV-2, overweight.

Graphical Abstract
[1]
Lenharo, M. WHO declares end to COVID-19’s emergency phase. Nature, 2023, 01559.
[http://dx.doi.org/10.1038/d41586-023-01559-z] [PMID: 37147368]
[2]
Vilches, TN; Sah, P; Moghadas, SM; Shoukat, A; Fitzpatrick, MC; Hotez, PJ; Schneider, EC; Galvani, AP COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. Lancet Reg. Heal Am., 2022, 6, 100147.
[3]
The Lancet. The COVID-19 pandemic in 2023: Far from over. Lancet, 2023, 401(10371), 79.
[http://dx.doi.org/10.1016/S0140-6736(23)00050-8] [PMID: 36641201]
[4]
Booth, A.; Reed, A.B.; Ponzo, S.; Yassaee, A.; Aral, M.; Plans, D.; Labrique, A.; Mohan, D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One, 2021, 16(3), e0247461.
[http://dx.doi.org/10.1371/journal.pone.0247461] [PMID: 33661992]
[5]
Ryan, P.M.; Caplice, N.M. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity, 2020, 28(7), 1191-1194.
[http://dx.doi.org/10.1002/oby.22843] [PMID: 32314868]
[6]
Tamara, A.; Tahapary, D.L. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab. Syndr., 2020, 14(4), 655-659.
[http://dx.doi.org/10.1016/j.dsx.2020.05.020] [PMID: 32438328]
[7]
Kassir, R. Risk of COVID‐19 for patients with obesity. Obes. Rev., 2020, 21, e13034.
[8]
William, D. Obesity and its implications for COVID-19 mortality. Obesity, 2020, 28, 1005-1005.
[http://dx.doi.org/10.1002/oby.22818] [PMID: 32237206]
[9]
Gerhart, J.G.; Balevic, S.; Sinha, J.; Perrin, E.M.; Wang, J.; Edginton, A.N.; Gonzalez, D. Characterizing pharmacokinetics in children with obesity-physiological, drug, patient, and methodological considerations. Front. Pharmacol., 2022, 13, 818726.
[http://dx.doi.org/10.3389/fphar.2022.818726] [PMID: 35359853]
[10]
Smit, C.; De Hoogd, S.; Brüggemann, R.J.M.; Knibbe, C.A.J. Obesity and drug pharmacology: A review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin. Drug Metab. Toxicol., 2018, 14(3), 275-285.
[http://dx.doi.org/10.1080/17425255.2018.1440287] [PMID: 29431542]
[11]
Barras, M.; Legg, A. Drug dosing in obese adults. Aust. Prescr., 2017, 40(5), 189-193.
[http://dx.doi.org/10.18773/austprescr.2017.053] [PMID: 29109603]
[12]
Han, P.Y.; Duffull, S.B.; Kirkpatrick, C.M.J.; Green, B. Dosing in obesity: A simple solution to a big problem. Clin. Pharmacol. Ther., 2007, 82(5), 505-508.
[http://dx.doi.org/10.1038/sj.clpt.6100381] [PMID: 17952107]
[13]
Morrish, G.A.; Pai, M.P.; Green, B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin. Drug Metab. Toxicol., 2011, 7(6), 697-706.
[http://dx.doi.org/10.1517/17425255.2011.570331] [PMID: 21417960]
[14]
Nwabufo, C.K.; Bendayan, R. Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends Pharmacol. Sci., 2022, 43(12), 1041-1054.
[http://dx.doi.org/10.1016/j.tips.2022.09.005] [PMID: 36374805]
[15]
Goldman, J.D.; Lye, D.C.B.; Hui, D.S.; Marks, K.M.; Bruno, R.; Montejano, R.; Spinner, C.D.; Galli, M.; Ahn, M.Y.; Nahass, R.G.; Chen, Y.S.; SenGupta, D.; Hyland, R.H.; Osinusi, A.O.; Cao, H.; Blair, C.; Wei, X.; Gaggar, A.; Brainard, D.M.; Towner, W.J.; Muñoz, J.; Mullane, K.M.; Marty, F.M.; Tashima, K.T.; Diaz, G.; Subramanian, A. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med., 2020, 383(19), 1827-1837.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]
[16]
Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236), 1569-1578.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[17]
Shargel, L.; Wu-Pong, S.; Yu, A.B.C. Introduction to biopharmaceutics and pharmacokinetics. In: Applied Biopharmaceutics; The McGraw-Hill Companies: New York, NY, 2012.
[18]
Saadeh, S. Nonalcoholic Fatty liver disease and obesity. Nutr. Clin. Pract., 2007, 22(1), 1-10.
[http://dx.doi.org/10.1177/011542650702200101] [PMID: 17242448]
[19]
Elfiky, A.A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 2020, 253, 117592.
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]
[20]
Adeoye, A.O.; Oso, B.J.; Olaoye, I.F.; Tijjani, H.; Adebayo, A.I. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. J. Biomol. Struct. Dyn., 2020, 1-11.
[PMID: 32375574]
[21]
Jain, M.K.; Zoellner, C. Role of ribavirin in HCV treatment response: Now and in the future. Expert Opin. Pharmacother., 2010, 11(4), 673-683.
[http://dx.doi.org/10.1517/14656560903580001] [PMID: 20163278]
[22]
Jácome, R.; Campillo-Balderas, J.A.; Ponce de León, S.; Becerra, A.; Lazcano, A. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci. Rep., 2020, 10(1), 9294.
[http://dx.doi.org/10.1038/s41598-020-66440-9] [PMID: 32518317]
[23]
Kirby, B.J.; Symonds, W.T.; Kearney, B.P.; Mathias, A.A. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C Virus NS5B polymerase inhibitor sofosbuvir. Clin. Pharmacokinet., 2015, 54(7), 677-690.
[http://dx.doi.org/10.1007/s40262-015-0261-7] [PMID: 25822283]
[24]
Mogalian, E.; Brainard, D.M.; Osinusi, A.; Moorehead, L.; Murray, B.; Ling, K.H.J.; Perry, R.; Curtis, C.; Lawitz, E.; Lasseter, K.; Marbury, T.; Mathias, A. Pharmacokinetics and safety of velpatasvir and sofosbuvir/velpatasvir in subjects with hepatic impairment. Clin. Pharmacokinet., 2018, 57(11), 1449-1457.
[http://dx.doi.org/10.1007/s40262-018-0645-6] [PMID: 29520729]
[25]
Salvi, R.; Patankar, P. Emerging pharmacotherapies for COVID-19. Biomed. Pharmacother., 2020, 128, 110267.
[http://dx.doi.org/10.1016/j.biopha.2020.110267] [PMID: 32410772]
[26]
Jain, R.; Chung, S.M.; Jain, L.; Khurana, M.; Lau, S.W.J.; Lee, J.E.; Vaidyanathan, J.; Zadezensky, I.; Choe, S.; Sahajwalla, C.G. Implications of obesity for drug therapy: Limitations and challenges. Clin. Pharmacol. Ther., 2011, 90(1), 77-89.
[http://dx.doi.org/10.1038/clpt.2011.104] [PMID: 21633345]
[27]
Leden, I. Digoxin-hydroxychloroquine interaction? Acta Med. Scand., 1982, 211(5), 411-412.
[http://dx.doi.org/10.1111/j.0954-6820.1982.tb01971.x] [PMID: 7113754]
[28]
Somer, M.; Kallio, J.; Pesonen, U.; Pyykkö, K.; Huupponen, R.; Scheinin, M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol., 2000, 49(6), 549-554.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00197.x] [PMID: 10848718]
[29]
Tsai, D.; Jamal, J.A.; Davis, J.S.; Lipman, J.; Roberts, J.A. Interethnic differences in pharmacokinetics of antibacterials. Clin. Pharmacokinet., 2015, 54(3), 243-260.
[http://dx.doi.org/10.1007/s40262-014-0209-3] [PMID: 25385446]
[30]
Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; Tao, L.; Zhang, H. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem., 2016, 291(17), 9218-9232.
[http://dx.doi.org/10.1074/jbc.M116.716100] [PMID: 26953343]
[31]
Pea, F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr. Clin. Pharmacol., 2013, 8(1), 5-12.
[PMID: 22946868]
[32]
Byrne, C.J.; Parton, T.; McWhinney, B.; Fennell, J.P.; O’Byrne, P.; Deasy, E.; Egan, S.; Enright, H.; Desmond, R.; Ryder, S.A.; D’Arcy, D.M.; McHugh, J.; Roberts, J.A. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J. Antimicrob. Chemother., 2018, 73(4), 995-1003.
[http://dx.doi.org/10.1093/jac/dkx473] [PMID: 29272419]
[33]
Liu, J.; Li, S.; Liu, J.; Liang, B.; Wang, X.; Wang, H.; Li, W.; Tong, Q.; Yi, J.; Zhao, L.; Xiong, L.; Guo, C.; Tian, J.; Luo, J.; Yao, J.; Pang, R.; Shen, H.; Peng, C.; Liu, T.; Zhang, Q.; Wu, J.; Xu, L.; Lu, S.; Wang, B.; Weng, Z.; Han, C.; Zhu, H.; Zhou, R.; Zhou, H.; Chen, X.; Ye, P.; Zhu, B.; Wang, L.; Zhou, W.; He, S.; He, Y.; Jie, S.; Wei, P.; Zhang, J.; Lu, Y.; Wang, W.; Zhang, L.; Li, L.; Zhou, F.; Wang, J.; Dittmer, U.; Lu, M.; Hu, Y.; Yang, D.; Zheng, X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine, 2020, 55, 102763.
[http://dx.doi.org/10.1016/j.ebiom.2020.102763] [PMID: 32361250]
[34]
Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, 46(5), 846-848.
[http://dx.doi.org/10.1007/s00134-020-05991-x] [PMID: 32125452]
[35]
Frey, N.; Grange, S.; Woodworth, T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol., 2010, 50(7), 754-766.
[http://dx.doi.org/10.1177/0091270009350623] [PMID: 20097931]
[36]
Abdallah, H.; Hsu, J.C.; Lu, P.; Fettner, S.; Zhang, X.; Douglass, W.; Bao, M.; Rowell, L.; Burmester, G.R.; Kivitz, A. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J. Clin. Pharmacol., 2017, 57(4), 459-468.
[http://dx.doi.org/10.1002/jcph.826] [PMID: 27599663]
[37]
Huet, T.; Beaussier, H.; Voisin, O.; Jouveshomme, S.; Dauriat, G.; Lazareth, I.; Sacco, E.; Naccache, J.M.; Bézie, Y.; Laplanche, S.; Le Berre, A.; Le Pavec, J.; Salmeron, S.; Emmerich, J.; Mourad, J.J.; Chatellier, G.; Hayem, G. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol., 2020, 2(7), e393-e400.
[http://dx.doi.org/10.1016/S2665-9913(20)30164-8] [PMID: 32835245]
[38]
Yang, B.; Frazier, J.; McCabe, D.; Young, J. FRI0036 Population pharmacokinetics (pk) of anakinra in subjects with rheumatoid arthritis (ra). Speaker abstracts 2001, vol. 60. BMJ, 2001, A459, 3-A460.
[39]
Cohen, S.; Hurd, E.; Cush, J.; Schiff, M.; Weinblatt, M.E.; Moreland, L.W.; Kremer, J.; Bear, M.B.; Rich, W.J.; McCabe, D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46(3), 614-624.
[http://dx.doi.org/10.1002/art.10141] [PMID: 11920396]
[40]
Adcock, I.M.; Mumby, S. Glucocorticoids. Handb. Exp. Pharmacol., 2016, 237, 171-196.
[41]
Czock, D.; Keller, F.; Rasche, F.M.; Häussler, U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet., 2005, 44(1), 61-98.
[http://dx.doi.org/10.2165/00003088-200544010-00003] [PMID: 15634032]
[42]
Dunn, T.E.; Ludwig, E.A.; Slaughter, R.L.; Camara, D.S.; Jusko, W.J. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin. Pharmacol. Ther., 1991, 49(5), 536-549.
[http://dx.doi.org/10.1038/clpt.1991.64] [PMID: 1827621]
[43]
Valsamakis, G.; Anwar, A.; Tomlinson, J.W.; Shackleton, C.H.L.; McTernan, P.G.; Chetty, R.; Wood, P.J.; Banerjee, A.K.; Holder, G.; Barnett, A.H.; Stewart, P.M.; Kumar, S. 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 2004, 89(9), 4755-4761.
[http://dx.doi.org/10.1210/jc.2003-032240] [PMID: 15356090]
[44]
Derendorf, H.; Rohdewald, P.; Möllmann, H.; Rehder, J.; Barth, J.; Neveling, D. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Biopharm. Drug Dispos., 1985, 6(4), 423-432.
[http://dx.doi.org/10.1002/bdd.2510060408] [PMID: 4084667]
[45]
Milsap, R.L.; Plaisance, K.I.; Jusko, W.J. Prednisolone disposition in obese men. Clin. Pharmacol. Ther., 1984, 36(6), 824-831.
[http://dx.doi.org/10.1038/clpt.1984.263] [PMID: 6499362]
[46]
Xu, J.; Nave, R.; Lahu, G.; Derom, E.; Derendorf, H. Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J. Clin. Pharmacol., 2010, 50(10), 1118-1127.
[http://dx.doi.org/10.1177/0091270009354994] [PMID: 20150524]
[47]
Mårs, U.; d’Argy, R.; Hallbeck, K.; Miller-Larsson, A.; Edsbäcker, S. Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice. Basic Clin. Pharmacol. Toxicol., 2013, 112(6), 401-411.
[http://dx.doi.org/10.1111/bcpt.12043] [PMID: 23256845]
[48]
Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178, 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[49]
Muñoz, J.; Ballester, M.R.; Antonijoan, R.M.; Gich, I.; Rodríguez, M.; Colli, E.; Gold, S.; Krolewiecki, A.J. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl. Trop. Dis., 2018, 12(1), e0006020.
[http://dx.doi.org/10.1371/journal.pntd.0006020] [PMID: 29346388]
[50]
Bassissi, M.F.; Alvinerie, M.; Lespine, A. Macrocyclic lactones: Distribution in plasma lipoproteins of several animal species including humans. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2004, 138(4), 437-444.
[http://dx.doi.org/10.1016/j.cca.2004.07.011] [PMID: 15536051]
[51]
Ballent, M.; Lifschitz, A.; Virkel, G.; Sallovitz, J.; Lanusse, C. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: In vitro and in vivo assessments. Drug Metab. Dispos., 2006, 34(3), 457-463.
[http://dx.doi.org/10.1124/dmd.105.007757] [PMID: 16381664]
[52]
Tumminia, A.; Romano, R.; Brugaletta, G.; Scicali, R.; Biondi, G.; Oliveri, R.; Romano, M.; San Lio, P.M. The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. Nutr. Metab. Cardiovasc. Dis., 2022, 32(7), 1635-1641.
[http://dx.doi.org/10.1016/j.numecd.2022.04.005] [PMID: 35508458]
[53]
So, M.; Takahashi, M.; Miyamoto, Y.; Ishisaka, Y.; Iwagami, M.; Tsugawa, Y.; Egorova, N.N.; Kuno, T. The effect of obesity on in-hospital mortality among patients with COVID-19 receiving corticosteroids. Diabetes Metab. Syndr., 2022, 16(1), 102373.
[http://dx.doi.org/10.1016/j.dsx.2021.102373] [PMID: 34979344]
[54]
Fioravanti, A.; Porcelli, B.; Terzuoli, L.; Bacarelli, M.R.; Tenti, S.; Cheleschi, S. Tocilizumab, adipokines and severe complications of COVID-19. Clin. Drug Investig., 2020, 40(9), 891-892.
[http://dx.doi.org/10.1007/s40261-020-00950-2] [PMID: 32661912]
[55]
Marconi, V.C.; Ramanan, A.V.; de Bono, S.; Kartman, C.E.; Krishnan, V.; Liao, R.; Piruzeli, M.L.B.; Goldman, J.D.; Alatorre-Alexander, J.; de Cassia Pellegrini, R.; Estrada, V.; Som, M.; Cardoso, A.; Chakladar, S.; Crowe, B.; Reis, P.; Zhang, X.; Adams, D.H.; Ely, E.W.; Ahn, M-Y.; Akasbi, M.; Alatorre-Alexander, J.; Altclas, J.D.; Ariel, F.; Ariza, H.A.; Atkar, C.; Bertetti, A.; Bhattacharya, M.; Briones, M.L.; Budhraja, A.; Burza, A.; Camacho Ortiz, A.; Caricchio, R.; Casas, M.; Cevoli Recio, V.; Choi, W.S.; Cohen, E.; Comulada-Rivera, A.; Cook, P.; Cornejo Juarez, D.P.; Daniel, C.; Degrecci Relvas, L.F.; Dominguez Cherit, J.G.; Ellerin, T.; Enikeev, D.; Erico Tanni Minamoto, S.; Estrada, V.; Fiss, E.; Furuichi, M.; Giovanni Luz, K.; Goldman, J.D.; Gonzalez, O.; Gordeev, I.; Gruenewald, T.; Hamamoto Sato, V.A.; Heo, E.Y.; Heo, J.Y.; Hermida, M.; Hirai, Y.; Hutchinson, D.; Iastrebner, C.; Ioachimescu, O.; Jain, M.; Juliani Souza Lima, M.P.; Khan, A.; Kremer, A.E.; Lawrie, T.; MacElwee, M.; Madhani-Lovely, F.; Malhotra, V.; Martínez Resendez, M.F.; McKinnell, J.; Milligan, P.; Minelli, C.; Moran Rodriguez, M.A.; Parody, M.L.; Paulin, P.; Pellegrini, R.C.; Pemu, P.; Procopio Carvalho, A.C.; Puoti, M.; Purow, J.; Ramesh, M.; Rea Neto, A.; Rea Neto, A.; Robinson, P.; Rodrigues, C.; Rojas Velasco, G.; Saraiva, J.F.K.; Scheinberg, M.; Schreiber, S.; Scublinsky, D.; Sevciovic Grumach, A.; Shawa, I.; Simon Campos, J.; Sofat, N.; Som, M.; Spinner, C.D.; Sprinz, E.; Stienecker, R.; Suarez, J.; Tachikawa, N.; Tahir, H.; Tiffany, B.; Vishnevsky, A.; Westheimer Cavalcante, A.; Zirpe, K. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med., 2021, 9(12), 1407-1418.
[http://dx.doi.org/10.1016/S2213-2600(21)00331-3] [PMID: 34480861]
[56]
Barletta, J.F.; Erstad, B.L. Drug dosing in hospitalized obese patients with COVID-19. Crit. Care, 2022, 26(1), 60.
[http://dx.doi.org/10.1186/s13054-022-03941-1] [PMID: 35287690]
[57]
Hanley, M.J.; Abernethy, D.R.; Greenblatt, D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet., 2010, 49(2), 71-87.
[http://dx.doi.org/10.2165/11318100-000000000-00000] [PMID: 20067334]
[58]
Berezhkovskiy, L.M. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J. Pharm. Sci., 2011, 100(6), 2482-2497.
[http://dx.doi.org/10.1002/jps.22444] [PMID: 21254063]
[59]
Benedek, I.H. Fiske d, W.D.; Griffen, W.O.; Bell, R.M.; Blouin, R.A.; McNamara, P.J. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br. J. Clin. Pharmacol., 1983, 16(6), 751-754.
[http://dx.doi.org/10.1111/j.1365-2125.1983.tb02258.x] [PMID: 6661365]
[60]
Blouin, R.A.; Warren, G.W. Pharmacokinetic considerations in obesity. J. Pharm. Sci., 1999, 88(1), 1-7.
[http://dx.doi.org/10.1021/js980173a] [PMID: 9874695]
[61]
Núñez-Ruiz, A.; Sánchez-Brena, F.; López-Pacheco, C.; Acevedo-Domínguez, N.A.; Soldevila, G. Obesity modulates the immune macroenvironment associated with breast cancer development. PLoS One, 2022, 17(4), e0266827.
[http://dx.doi.org/10.1371/journal.pone.0266827] [PMID: 35472214]
[62]
Xiao, J.; Shen, K.; Liu, K.; Wang, Y.; Fan, H.; Cheng, Q.; Zhou, X.; Hu, L.; Wang, G.; Xu, Z.; Yang, L. Obesity promotes lipid accumulation in lymph node metastasis of gastric cancer: A retrospective case-control study. Lipids Health Dis., 2022, 21, 123.
[63]
Heymsfield, S.B.; Wadden, T.A.; Kalangi, S.K. Mechanisms, pathophysiology, and management of obesity. N. Engl. J. Med., 2017, 376, 254-266.
[64]
Alti, D.; Sambamurthy, C.; Kalangi, S.K. Emergence of leptin in infection and immunity: Scope and challenges in vaccines formulation. Front. Cell. Infect. Microbiol., 2018, 8, 147.
[http://dx.doi.org/10.3389/fcimb.2018.00147] [PMID: 29868503]
[65]
Popkin, B.M.; Du, S.; Green, W.D.; Beck, M.A.; Algaith, T.; Herbst, C.H.; Alsukait, R.F.; Alluhidan, M.; Alazemi, N.; Shekar, M. Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships. Obes. Rev., 2020, 21(11), e13128.
[http://dx.doi.org/10.1111/obr.13128] [PMID: 32845580]
[66]
Kane, H.; Lynch, L. Innate immune control of adipose tissue homeostasis. Trends Immunol., 2019, 40(9), 857-872.
[http://dx.doi.org/10.1016/j.it.2019.07.006] [PMID: 31399336]
[67]
Khanna, D.; Khanna, S.; Khanna, P.; Kahar, P.; Patel, B.M. Obesity: A chronic low-grade inflammation and its markers. Cureus, 2022, 14(2), e22711.
[http://dx.doi.org/10.7759/cureus.22711] [PMID: 35386146]
[68]
Chait, A.; den Hartigh, L.J. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front. Cardiovasc. Med., 2020, 7, 22.
[http://dx.doi.org/10.3389/fcvm.2020.00022] [PMID: 32158768]
[69]
Karlsson, E.A.; Sheridan, P.A.; Beck, M.A. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J. Immunol., 2010, 184(6), 3127-3133.
[http://dx.doi.org/10.4049/jimmunol.0903220] [PMID: 20173021]
[70]
Karlsson, E.A.; Beck, M.A. The burden of obesity on infectious disease. Exp. Biol. Med., 2010, 235(12), 1412-1424.
[http://dx.doi.org/10.1258/ebm.2010.010227] [PMID: 21127339]
[71]
Aziz, R.; Sherwani, A.Y.; Al Mahri, S.; Malik, S.S.; Mohammad, S. Why are obese people predisposed to severe disease in viral respiratory infections? Obesities, 2023, 3(1), 46-58.
[http://dx.doi.org/10.3390/obesities3010005]
[72]
Callaway, E. The race for coronavirus vaccines: A graphical guide. Nature, 2020, 580(7805), 576-577.
[http://dx.doi.org/10.1038/d41586-020-01221-y] [PMID: 32346146]
[73]
Forni, G.; Mantovani, A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ., 2021, 28(2), 626-639.
[http://dx.doi.org/10.1038/s41418-020-00720-9] [PMID: 33479399]
[74]
Machado, B.A.S.; Hodel, K.V.S.; Fonseca, L.M.S.; Mascarenhas, L.A.B.; Andrade, L.P.C.S.; Rocha, V.P.C.; Soares, M.B.P.; Berglund, P.; Duthie, M.S.; Reed, S.G.; Badaró, R. The importance of RNA-based vaccines in the fight against COVID-19: An overview. Vaccines, 2021, 9(11), 1345.
[http://dx.doi.org/10.3390/vaccines9111345] [PMID: 34835276]
[75]
Ledford, H. Moderna COVID vaccine becomes second to get US authorization. Nature, 2020.
[http://dx.doi.org/10.1038/d41586-020-03593-7] [PMID: 33340017]
[76]
Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; Bailey, R.; Swanson, K.A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W.V.; Cooper, D.; Frenck, R.W., Jr; Hammitt, L.L.; Türeci, Ö.; Nell, H.; Schaefer, A.; Ünal, S.; Tresnan, D.B.; Mather, S.; Dormitzer, P.R.; Şahin, U.; Jansen, K.U.; Gruber, W.C. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med., 2020, 383(27), 2603-2615.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[77]
Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; McGettigan, J.; Khetan, S.; Segall, N.; Solis, J.; Brosz, A.; Fierro, C.; Schwartz, H.; Neuzil, K.; Corey, L.; Gilbert, P.; Janes, H.; Follmann, D.; Marovich, M.; Mascola, J.; Polakowski, L.; Ledgerwood, J.; Graham, B.S.; Bennett, H.; Pajon, R.; Knightly, C.; Leav, B.; Deng, W.; Zhou, H.; Han, S.; Ivarsson, M.; Miller, J.; Zaks, T. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med., 2021, 384(5), 403-416.
[http://dx.doi.org/10.1056/NEJMoa2035389] [PMID: 33378609]
[78]
Sadoff, J.; Gray, G.; Vandebosch, A.; Cárdenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; Offergeld, K.; Scheper, G.; Taylor, K.L.; Robb, M.L.; Treanor, J.; Barouch, D.H.; Stoddard, J.; Ryser, M.F.; Marovich, M.A.; Neuzil, K.M.; Corey, L.; Cauwenberghs, N.; Tanner, T.; Hardt, K.; Ruiz-Guiñazú, J.; Le Gars, M.; Schuitemaker, H.; Van Hoof, J.; Struyf, F.; Douoguih, M. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med., 2021, 384(23), 2187-2201.
[http://dx.doi.org/10.1056/NEJMoa2101544] [PMID: 33882225]
[79]
Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; Sproule, S.; Robb, M.L.; Corey, L.; Neuzil, K.M.; Hahn, W.; Hunt, J.; Mulligan, M.J.; McEvoy, C.; DeJesus, E.; Hassman, M.; Little, S.J.; Pahud, B.A.; Durbin, A.; Pickrell, P.; Daar, E.S.; Bush, L.; Solis, J.; Carr, Q.O.; Oyedele, T.; Buchbinder, S.; Cowden, J.; Vargas, S.L.; Guerreros Benavides, A.; Call, R.; Keefer, M.C.; Kirkpatrick, B.D.; Pullman, J.; Tong, T.; Brewinski Isaacs, M.; Benkeser, D.; Janes, H.E.; Nason, M.C.; Green, J.A.; Kelly, E.J.; Maaske, J.; Mueller, N.; Shoemaker, K.; Takas, T.; Marshall, R.P.; Pangalos, M.N.; Villafana, T.; Gonzalez-Lopez, A. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med., 2021, 385(25), 2348-2360.
[http://dx.doi.org/10.1056/NEJMoa2105290] [PMID: 34587382]
[80]
Falagas, M.E.; Athanasoulia, A.P.; Peppas, G.; Karageorgopoulos, D.E. Effect of body mass index on the outcome of infections: A systematic review. Obes. Rev., 2009, 10(3), 280-289.
[http://dx.doi.org/10.1111/j.1467-789X.2008.00546.x] [PMID: 19243518]
[81]
Eliakim, A.; Swindt, C.; Zaldivar, F.; Casali, P.; Cooper, D.M. Reduced tetanus antibody titers in overweight children. Autoimmunity, 2006, 39(2), 137-141.
[http://dx.doi.org/10.1080/08916930600597326] [PMID: 16698670]
[82]
Ealey, K.N.; Phillips, J.; Sung, H.K. COVID-19 and obesity: Fighting two pandemics with intermittent fasting. Trends Endocrinol. Metab., 2021, 32(9), 706-720.
[http://dx.doi.org/10.1016/j.tem.2021.06.004] [PMID: 34275726]
[83]
Frasca, D.; Reidy, L.; Cray, C.; Diaz, A.; Romero, M.; Kahl, K.; Blomberg, B.B. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One, 2021, 16(3), e0245424.
[http://dx.doi.org/10.1371/journal.pone.0245424] [PMID: 33760825]
[84]
Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Gino, E.; Domenico, D.; Di Bella, O. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. MedRxiv, 2021, 2021.
[85]
Ou, X.; Jiang, J.; Lin, B.; Liu, Q.; Lin, W.; Chen, G.; Wen, J. Antibody responses to COVID‐19 vaccination in people with obesity: A systematic review and meta‐analysis. Influenza Other Respir. Viruses, 2023, 17(1), e13078.
[http://dx.doi.org/10.1111/irv.13078] [PMID: 36535669]
[86]
Szczerbiński, Ł.; Okruszko, M.A.; Szabłowski, M.; Warpechowski, J.; Paszko, A.; Citko, A.; Konopka, P.; Bauer, W.; Krętowski, A.J. Immune response to vaccination against covid-19 at different second-dose intervals and their associations with metabolic parameters. Vaccines, 2023, 11(1), 149.
[http://dx.doi.org/10.3390/vaccines11010149] [PMID: 36679994]
[87]
Watanabe, M.; Balena, A.; Tuccinardi, D.; Tozzi, R.; Risi, R.; Masi, D.; Caputi, A.; Rossetti, R.; Spoltore, M.E.; Filippi, V.; Gangitano, E.; Manfrini, S.; Mariani, S.; Lubrano, C.; Lenzi, A.; Mastroianni, C.; Gnessi, L. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine. Diabetes Metab. Res. Rev., 2022, 38(1), e3465.
[http://dx.doi.org/10.1002/dmrr.3465] [PMID: 33955644]
[88]
Uysal, E.B.; Gümüş, S.; Bektöre, B.; Bozkurt, H.; Gözalan, A. Evaluation of antibody response after COVID‐19 vaccination of healthcare workers. J. Med. Virol., 2022, 94(3), 1060-1066.
[http://dx.doi.org/10.1002/jmv.27420] [PMID: 34704620]
[89]
Lee, S.W.; Moon, J.Y.; Lee, S.K.; Lee, H.; Moon, S.; Chung, S.J.; Yeo, Y.; Park, T.S.; Park, D.W.; Kim, T.H.; Sohn, J.W.; Yoon, H.J.; Kim, S.H. Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions. Front. Immunol., 2021, 12, 779212.
[http://dx.doi.org/10.3389/fimmu.2021.779212] [PMID: 34899739]
[90]
Rudolph, A.; Mitchell, J.; Barrett, J.; Sköld, H.; Taavola, H.; Erlanson, N.; Melgarejo-González, C.; Yue, Q.Y. Global safety monitoring of COVID-19 vaccines: How pharmacovigilance rose to the challenge. Ther. Adv. Drug Saf., 2022, 13.
[http://dx.doi.org/10.1177/20420986221118972] [PMID: 36052399]
[91]
Oosterhuis, I.; Scholl, J.; van Puijenbroek, E.; Kant, A.; van Hunsel, F. Optimizing safety surveillance for covid-19 vaccines at the national pharmacovigilance centre lareb: One Year of COVID-19 vaccine experience. Drug Saf., 2023, 46(1), 65-75.
[http://dx.doi.org/10.1007/s40264-022-01253-5] [PMID: 36350465]
[92]
Crommelynck, S.; Thill, P. Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France. Infect. Dis. Now, 2022, 52(8), S16-S18.
[http://dx.doi.org/10.1016/j.idnow.2022.09.018] [PMID: 36152793]
[93]
Amancio-Chassin, O. Pharmacovigilance in the vaccination program against coronavirus disease 19. Revista Medica del Hospital General de M xico, 2021, 84(3), 92-95.
[http://dx.doi.org/10.24875/HGMX.M21000041]
[94]
Naniche, D.; Hotez, P.; Bottazzi, M.E.; Ergonul, O.; Figueroa, J.P.; Gilbert, S.; Gursel, M.; Hassanain, M.; Kang, G.; Kaslow, D.; Kim, J.H.; Lall, B.; Larson, H.; Sheahan, T.; Shoham, S.; Wilder-Smith, A.; Sow, S.O.; Strub-Wourgaft, N.; Yadav, P.; Batista, C. Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine, 2021, 36, 100925.
[http://dx.doi.org/10.1016/j.eclinm.2021.100925] [PMID: 34099998]
[95]
Bhandari, B.; Rayamajhi, G.; Lamichhane, P.; Shenoy, A.K. Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review. BioMed Res. Int., 2022, 2022, 1-11.
[http://dx.doi.org/10.1155/2022/2911333] [PMID: 36017393]
[96]
Kadali, R.A.K.; Janagama, R.; Peruru, S.; Gajula, V.; Madathala, R.R.; Chennaiahgari, N.; Malayala, S.V. Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms. J. Med. Virol., 2021, 93(7), 4420-4429.
[http://dx.doi.org/10.1002/jmv.26996] [PMID: 33822361]
[97]
Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevila, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; Hu, C.; Selvachandran, S.; Antonelli, M.; Murray, B.; Canas, L.S.; Molteni, E.; Graham, M.S.; Modat, M.; Joshi, A.D.; Mangino, M.; Hammers, A.; Goodman, A.L.; Chan, A.T.; Wolf, J.; Steves, C.J.; Valdes, A.M.; Ourselin, S.; Spector, T.D. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect. Dis., 2021, 21(7), 939-949.
[http://dx.doi.org/10.1016/S1473-3099(21)00224-3] [PMID: 33930320]
[98]
Doroftei, B.; Ciobica, A.; Ilie, O.D.; Maftei, R.; Ilea, C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4), 579.
[http://dx.doi.org/10.3390/diagnostics11040579] [PMID: 33804914]
[99]
Ledford, H. COVID vaccines and blood clots: What researchers know so far. Nature, 2021, 596, 479-481.
[http://dx.doi.org/10.1038/d41586-021-02291-2]
[100]
Aryal, S.; Shrestha, A. Adverse events following immunization with Sinopharm (Vero Cell), inactivated COVID-19 vaccine. J. Patan Acad. Heal. Sci., 2021, 8, 18-24.
[http://dx.doi.org/10.3126/jpahs.v8i2.31099]
[101]
Riad, A.; Sağıroğlu, D.; Üstün, B.; Pokorná, A.; Klugarová, J.; Attia, S.; Klugar, M. Article prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in turkey. J. Clin. Med., 2021, 10(12), 2629.
[http://dx.doi.org/10.3390/jcm10122629] [PMID: 34203769]
[102]
Woo, E.J.; Mba-Jonas, A.; Thomas, A.; Baer, B.; Day, B.; Kim, Y.; Gomez-Lorenzo, M.; Nair, N. Thromboembolic events after Ad.26. COV2. S COVID ‐19 vaccine: Reports to the Vaccine Adverse Event Reporting System. Pharmacoepidemiol. Drug Saf., 2022, 31(11), 1174-1181.
[http://dx.doi.org/10.1002/pds.5523] [PMID: 36065046]
[103]
Wang, G.L.; Wang, Z.Y.; Duan, L.J.; Meng, Q.C.; Jiang, M.D.; Cao, J.; Yao, L.; Zhu, K.L.; Cao, W.C.; Ma, M.J. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N. Engl. J. Med., 2021, 384(24), 2354-2356.
[http://dx.doi.org/10.1056/NEJMc2103022] [PMID: 33822491]
[104]
Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; Robertson, D.L. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol., 2021, 19(7), 409-424.
[http://dx.doi.org/10.1038/s41579-021-00573-0] [PMID: 34075212]
[105]
Engelbrecht, F.A.; Scholes, R.J. Test for Covid-19 seasonality and the risk of second waves. One Health, 2021, 12, 100202.
[http://dx.doi.org/10.1016/j.onehlt.2020.100202] [PMID: 33283035]
[106]
Callaway, E. Beyond Omicron: What’s next for COVID’s viral evolution. Nature, 2021, 600(7888), 204-207.
[http://dx.doi.org/10.1038/d41586-021-03619-8] [PMID: 34876665]
[107]
Dicker, D.; Golan, R.; Baker, J.L.; Busetto, L.; Frühbeck, G.; Goossens, G.H.; Halford, J.C.G.; Holm, J.C.; Woodward, E.; Farpour-Lambert, N.J. Vaccinating people with obesity for COVID-19: EASO call for action. Obes. Facts, 2021, 14(3), 334-335.
[http://dx.doi.org/10.1159/000516524] [PMID: 33915546]
[108]
Raveendran, A.V.; Jayadevan, R.; Sashidharan, S. Long COVID: An overview. Diabetes Metab. Syndr., 2021, 15(3), 869-875.
[http://dx.doi.org/10.1016/j.dsx.2021.04.007] [PMID: 33892403]
[109]
Membrilla, J.A.; Caronna, E.; Trigo-López, J.; González-Martínez, A.; Layos-Romero, A.; Pozo-Rosich, P.; Guerrero-Peral, Á.; Gago-Veiga, A.B.; Andrés-López, A.; Díaz de Terán, J. Persistent headache after COVID-19: Pathophysioloy, clinic and treatment. Neurol. Perspect., 2021, 1, S31-S36.
[http://dx.doi.org/10.1016/j.neurop.2021.10.003]
[110]
Yelin, D.; Margalit, I.; Nehme, M.; Bordas-Martínez, J.; Pistelli, F.; Yahav, D.; Guessous, I.; Durà-Miralles, X.; Carrozzi, L.; Shapira-Lichter, I.; Vetter, P.; Peleato-Catalan, D.; Tiseo, G.; Wirtheim, E.; Kaiser, L.; Gudiol, C.; Falcone, M.; Leibovici, L. Patterns of long COVID symptoms: A multi-center cross sectional study. J. Clin. Med., 2022, 11(4), 898.
[http://dx.doi.org/10.3390/jcm11040898] [PMID: 35207171]
[111]
Iqbal, F.M.; Lam, K.; Sounderajah, V.; Clarke, J.M.; Ashrafian, H.; Darzi, A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine, 2021, 36, 100899.
[http://dx.doi.org/10.1016/j.eclinm.2021.100899] [PMID: 34036253]
[112]
Azzolini, E.; Levi, R.; Sarti, R.; Pozzi, C.; Mollura, M.; Mantovani, A.; Rescigno, M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA, 2022, 328(7), 676-678.
[http://dx.doi.org/10.1001/jama.2022.11691] [PMID: 35796131]
[113]
Crook, H.; Raza, S.; Nowell, J.; Young, M.; Edison, P. Long covid—mechanisms, risk factors, and management. BMJ, 2021, 374(1648), n1648.
[http://dx.doi.org/10.1136/bmj.n1648] [PMID: 34312178]
[114]
Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; Ahluwalia, N.; Bikdeli, B.; Dietz, D.; Der-Nigoghossian, C.; Liyanage-Don, N.; Rosner, G.F.; Bernstein, E.J.; Mohan, S.; Beckley, A.A.; Seres, D.S.; Choueiri, T.K.; Uriel, N.; Ausiello, J.C.; Accili, D.; Freedberg, D.E.; Baldwin, M.; Schwartz, A.; Brodie, D.; Garcia, C.K.; Elkind, M.S.V.; Connors, J.M.; Bilezikian, J.P.; Landry, D.W.; Wan, E.Y. Post-acute COVID-19 syndrome. Nat. Med., 2021, 27(4), 601-615.
[http://dx.doi.org/10.1038/s41591-021-01283-z] [PMID: 33753937]
[115]
Vimercati, L.; De Maria, L.; Quarato, M.; Caputi, A.; Gesualdo, L.; Migliore, G.; Cavone, D.; Sponselli, S.; Pipoli, A.; Inchingolo, F.; Scarano, A.; Lorusso, F.; Stefanizzi, P.; Tafuri, S. Association between Long COVID and Overweight/Obesity. J. Clin. Med., 2021, 10(18), 4143.
[http://dx.doi.org/10.3390/jcm10184143] [PMID: 34575251]
[116]
Heubner, L.; Petrick, P.L.; Güldner, A.; Bartels, L.; Ragaller, M.; Mirus, M.; Rand, A.; Tiebel, O.; Beyer-Westendorf, J.; Rößler, M.; Schmitt, J.; Koch, T.; Spieth, P.M. Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. Sci. Rep., 2022, 12(1), 18418.
[http://dx.doi.org/10.1038/s41598-022-22107-1] [PMID: 36319681]
[117]
Xiang, M.; Wu, X.; Jing, H.; Novakovic, V.A.; Shi, J. The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Front. Cardiovasc. Med., 2023, 10, 1062491.
[http://dx.doi.org/10.3389/fcvm.2023.1062491] [PMID: 36824451]
[118]
Mattioli, A.V.; Coppi, F.; Nasi, M.; Pinti, M.; Gallina, S. Long COVID: A new challenge for prevention of obesity in women. Am. J. Lifestyle Med., 2023, 17(1), 164-168.
[http://dx.doi.org/10.1177/15598276221111054] [PMID: 36636391]
[119]
Evans, R.A.; Leavy, O.C.; Richardson, M.; Elneima, O.; McAuley, H.J.C.; Shikotra, A.; Singapuri, A.; Sereno, M.; Saunders, R.M.; Harris, V.C.; Houchen-Wolloff, L.; Aul, R.; Beirne, P.; Bolton, C.E.; Brown, J.S.; Choudhury, G.; Diar-Bakerly, N.; Easom, N.; Echevarria, C.; Fuld, J.; Hart, N.; Hurst, J.; Jones, M.G.; Parekh, D.; Pfeffer, P.; Rahman, N.M.; Rowland-Jones, S.L.; Shah, A.M.; Wootton, D.G.; Chalder, T.; Davies, M.J.; De Soyza, A.; Geddes, J.R.; Greenhalf, W.; Greening, N.J.; Heaney, L.G.; Heller, S.; Howard, L.S.; Jacob, J.; Jenkins, R.G.; Lord, J.M.; Man, W.D-C.; McCann, G.P.; Neubauer, S.; Openshaw, P.J.M.; Porter, J.C.; Rowland, M.J.; Scott, J.T.; Semple, M.G.; Singh, S.J.; Thomas, D.C.; Toshner, M.; Lewis, K.E.; Thwaites, R.S.; Briggs, A.; Docherty, A.B.; Kerr, S.; Lone, N.I.; Quint, J.; Sheikh, A.; Thorpe, M.; Zheng, B.; Chalmers, J.D.; Ho, L.P.; Horsley, A.; Marks, M.; Poinasamy, K.; Raman, B.; Harrison, E.M.; Wain, L.V.; Brightling, C.E.; Abel, K.; Adamali, H.; Adeloye, D.; Adeyemi, O.; Adrego, R.; Aguilar Jimenez, L.A.; Ahmad, S.; Ahmad Haider, N.; Ahmed, R.; Ahwireng, N.; Ainsworth, M.; Al-Sheklly, B.; Alamoudi, A.; Ali, M.; Aljaroof, M.; All, A.M.; Allan, L.; Allen, R.J.; Allerton, L.; Allsop, L.; Almeida, P.; Altmann, D.; Alvarez Corral, M.; Amoils, S.; Anderson, D.; Antoniades, C.; Arbane, G.; Arias, A.; Armour, C.; Armstrong, L.; Armstrong, N.; Arnold, D.; Arnold, H.; Ashish, A.; Ashworth, A.; Ashworth, M.; Aslani, S.; Assefa-Kebede, H.; Atkin, C.; Atkin, P.; Aung, H.; Austin, L.; Avram, C.; Ayoub, A.; Babores, M.; Baggott, R.; Bagshaw, J.; Baguley, D.; Bailey, L.; Baillie, J.K.; Bain, S.; Bakali, M.; Bakau, M.; Baldry, E.; Baldwin, D.; Ballard, C.; Banerjee, A.; Bang, B.; Barker, R.E.; Barman, L.; Barratt, S.; Barrett, F.; Basire, D.; Basu, N.; Bates, M.; Bates, A.; Batterham, R.; Baxendale, H.; Bayes, H.; Beadsworth, M.; Beckett, P.; Beggs, M.; Begum, M.; Bell, D.; Bell, R.; Bennett, K.; Beranova, E.; Bermperi, A.; Berridge, A.; Berry, C.; Betts, S.; Bevan, E.; Bhui, K.; Bingham, M.; Birchall, K.; Bishop, L.; Bisnauthsing, K.; Blaikely, J.; Bloss, A.; Bolger, A.; Bonnington, J.; Botkai, A.; Bourne, C.; Bourne, M.; Bramham, K.; Brear, L.; Breen, G.; Breeze, J.; Bright, E.; Brill, S.; Brindle, K.; Broad, L.; Broadley, A.; Brookes, C.; Broome, M.; Brown, A.; Brown, A.; Brown, J.; Brown, J.; Brown, M.; Brown, M.; Brown, V.; Brugha, T.; Brunskill, N.; Buch, M.; Buckley, P.; Bularga, A.; Bullmore, E.; Burden, L.; Burdett, T.; Burn, D.; Burns, G.; Burns, A.; Busby, J.; Butcher, R.; Butt, A.; Byrne, S.; Cairns, P.; Calder, P.C.; Calvelo, E.; Carborn, H.; Card, B.; Carr, C.; Carr, L.; Carson, G.; Carter, P.; Casey, A.; Cassar, M.; Cavanagh, J.; Chablani, M.; Chambers, R.C.; Chan, F.; Channon, K.M.; Chapman, K.; Charalambou, A.; Chaudhuri, N.; Checkley, A.; Chen, J.; Cheng, Y.; Chetham, L.; Childs, C.; Chilvers, E.R.; Chinoy, H.; Chiribiri, A.; Chong-James, K.; Choudhury, N.; Chowienczyk, P.; Christie, C.; Chrystal, M.; Clark, D.; Clark, C.; Clarke, J.; Clohisey, S.; Coakley, G.; Coburn, Z.; Coetzee, S.; Cole, J.; Coleman, C.; Conneh, F.; Connell, D.; Connolly, B.; Connor, L.; Cook, A.; Cooper, B.; Cooper, J.; Cooper, S.; Copeland, D.; Cosier, T.; Coulding, M.; Coupland, C.; Cox, E.; Craig, T.; Crisp, P.; Cristiano, D.; Crooks, M.G.; Cross, A.; Cruz, I.; Cullinan, P.; Cuthbertson, D.; Daines, L.; Dalton, M.; Daly, P.; Daniels, A.; Dark, P.; Dasgin, J.; David, A.; David, C.; Davies, E.; Davies, F.; Davies, G.; Davies, G.A.; Davies, K.; Dawson, J.; Daynes, E.; Deakin, B.; Deans, A.; Deas, C.; Deery, J.; Defres, S.; Dell, A.; Dempsey, K.; Denneny, E.; Dennis, J.; Dewar, A.; Dharmagunawardena, R.; Dickens, C.; Dipper, A.; Diver, S.; Diwanji, S.N.; Dixon, M.; Djukanovic, R.; Dobson, H.; Dobson, S.L.; Donaldson, A.; Dong, T.; Dormand, N.; Dougherty, A.; Dowling, R.; Drain, S.; Draxlbauer, K.; Drury, K.; Dulawan, P.; Dunleavy, A.; Dunn, S.; Earley, J.; Edwards, S.; Edwardson, C.; El-Taweel, H.; Elliott, A.; Elliott, K.; Ellis, Y.; Elmer, A.; Evans, D.; Evans, H.; Evans, J.; Evans, R.; Evans, R.I.; Evans, T.; Evenden, C.; Evison, L.; Fabbri, L.; Fairbairn, S.; Fairman, A.; Fallon, K.; Faluyi, D.; Favager, C.; Fayzan, T.; Featherstone, J.; Felton, T.; Finch, J.; Finney, S.; Finnigan, J.; Finnigan, L.; Fisher, H.; Fletcher, S.; Flockton, R.; Flynn, M.; Foot, H.; Foote, D.; Ford, A.; Forton, D.; Fraile, E.; Francis, C.; Francis, R.; Francis, S.; Frankel, A.; Fraser, E.; Free, R.; French, N.; Fu, X.; Furniss, J.; Garner, L.; Gautam, N.; George, J.; George, P.; Gibbons, M.; Gill, M.; Gilmour, L.; Gleeson, F.; Glossop, J.; Glover, S.; Goodman, N.; Goodwin, C.; Gooptu, B.; Gordon, H.; Gorsuch, T.; Greatorex, M.; Greenhaff, P.L.; Greenhalgh, A.; Greenwood, J.; Gregory, H.; Gregory, R.; Grieve, D.; Griffin, D.; Griffiths, L.; Guerdette, A-M.; Guillen Guio, B.; Gummadi, M.; Gupta, A.; Gurram, S.; Guthrie, E.; Guy, Z.; H Henson, H; Hadley, K.; Haggar, A.; Hainey, K.; Hairsine, B.; Haldar, P.; Hall, I.; Hall, L.; Halling-Brown, M.; Hamil, R.; Hancock, A.; Hancock, K.; Hanley, N.A.; Haq, S.; Hardwick, H.E.; Hardy, E.; Hardy, T.; Hargadon, B.; Harrington, K.; Harris, E.; Harrison, P.; Harvey, A.; Harvey, M.; Harvie, M.; Haslam, L.; Havinden-Williams, M.; Hawkes, J.; Hawkings, N.; Haworth, J.; Hayday, A.; Haynes, M.; Hazeldine, J.; Hazelton, T.; Heeley, C.; Heeney, J.L.; Heightman, M.; Henderson, M.; Hesselden, L.; Hewitt, M.; Highett, V.; Hillman, T.; Hiwot, T.; Hoare, A.; Hoare, M.; Hockridge, J.; Hogarth, P.; Holbourn, A.; Holden, S.; Holdsworth, L.; Holgate, D.; Holland, M.; Holloway, L.; Holmes, K.; Holmes, M.; Holroyd Hind, B.; Holt, L.; Hormis, A.; Hosseini, A.; Hotopf, M.; Howard, K.; Howell, A.; Hufton, E.; Hughes, A.D.; Hughes, J.; Hughes, R.; Humphries, A.; Huneke, N.; Hurditch, E.; Husain, M.; Hussell, T.; Hutchinson, J.; Ibrahim, W.; Ilyas, F.; Ingham, J.; Ingram, L.; Ionita, D.; Isaacs, K.; Ismail, K.; Jackson, T.; James, W.Y.; Jarman, C.; Jarrold, I.; Jarvis, H.; Jastrub, R.; Jayaraman, B.; Jezzard, P.; Jiwa, K.; Johnson, C.; Johnson, S.; Johnston, D.; Jolley, C.J.; Jones, D.; Jones, G.; Jones, H.; Jones, H.; Jones, I.; Jones, L.; Jones, S.; Jose, S.; Kabir, T.; Kaltsakas, G.; Kamwa, V.; Kanellakis, N.; Kaprowska,; Kausar, Z.; Keenan, N.; Kelly, S.; Kemp, G.; Kerslake, H.; Key, A.L.; Khan, F.; Khunti, K.; Kilroy, S.; King, B.; King, C.; Kingham, L.; Kirk, J.; Kitterick, P.; Klenerman, P.; Knibbs, L.; Knight, S.; Knighton, A.; Kon, O.; Kon, S.; Kon, S.S.; Koprowska, S.; Korszun, A.; Koychev, I.; Kurasz, C.; Kurupati, P.; Laing, C.; Lamlum, H.; Landers, G.; Langenberg, C.; Lasserson, D.; Lavelle Langham, L.; Lawrie, A.; Lawson, C.; Lawson, C.; Layton, A.; Lea, A.; Lee, D.; Lee, J-H.; Lee, E.; Leitch, K.; Lenagh, R.; Lewis, D.; Lewis, J.; Lewis, V.; Lewis-Burke, N.; Li, X.; Light, T.; Lightstone, L.; Lilaonitkul, W.; Lim, L.; Linford, S.; Lingford Hughes, A.; Lipman, M.; Liyanage, K.; Lloyd, A.; Logan, S.; Lomas, D.; Loosley, R.; Lota, H.; Lovegrove, W.; Lucey, A.; Lukaschuk, E.; Lye, A.; Lynch, C.; MacDonald, S.; MacGowan, G.; Macharia, I.; Mackie, J.; Macliver, L.; Madathil, S.; Madzamba, G.; Magee, N.; Magtoto, M.M.; Mairs, N.; Majeed, N.; Major, E.; Malein, F.; Malim, M.; Mallison, G.; Mandal, S.; Mangion, K.; Manisty, C.; Manley, R.; March, K.; Marciniak, S.; Marino, P.; Mariveles, M.; Marouzet, E.; Marsh, S.; Marshall, B.; Marshall, M.; Martin, J.; Martineau, A.; Martinez, L.M.; Maskell, N.; Matila, D.; Matimba-Mupaya, W.; Matthews, L.; Mbuyisa, A.; McAdoo, S.; Weir McCall, J.; McAllister-Williams, H.; McArdle, A.; McArdle, P.; McAulay, D.; McCormick, J.; McCormick, W.; McCourt, P.; McGarvey, L.; McGee, C.; Mcgee, K.; McGinness, J.; McGlynn, K.; McGovern, A.; McGuinness, H.; McInnes, I.B.; McIntosh, J.; McIvor, E.; McIvor, K.; McLeavey, L.; McMahon, A.; McMahon, M.J.; McMorrow, L.; Mcnally, T.; McNarry, M.; McNeill, J.; McQueen, A.; McShane, H.; Mears, C.; Megson, C.; Megson, S.; Mehta, P.; Meiring, J.; Melling, L.; Mencias, M.; Menzies, D.; Merida, Morillas, M.; Michael, A.; Milligan, L.; Miller, C.; Mills, C.; Mills, N.L.; Milner, L.; Misra, S.; Mitchell, J.; Mohamed, A.; Mohamed, N.; Mohammed, S.; Molyneaux, P.L.; Monteiro, W.; Moriera, S.; Morley, A.; Morrison, L.; Morriss, R.; Morrow, A.; Moss, A.J.; Moss, P.; Motohashi, K.; Msimanga, N.; Mukaetova-Ladinska, E.; Munawar, U.; Murira, J.; Nanda, U.; Nassa, H.; Nasseri, M.; Neal, A.; Needham, R.; Neill, P.; Newell, H.; Newman, T.; Newton-Cox, A.; Nicholson, T.; Nicoll, D.; Nolan, C.M.; Noonan, M.J.; Norman, C.; Novotny, P.; Nunag, J.; Nwafor, L.; Nwanguma, U.; Nyaboko, J.; O’Donnell, K.; O’Brien, C.; O’Brien, L.; O’Regan, D.; Odell, N.; Ogg, G.; Olaosebikan, O.; Oliver, C.; Omar, Z.; Orriss-Dib, L.; Osborne, L.; Osbourne, R.; Ostermann, M.; Overton, C.; Owen, J.; Oxton, J.; Pack, J.; Pacpaco, E.; Paddick, S.; Painter, S.; Pakzad, A.; Palmer, S.; Papineni, P.; Paques, K.; Paradowski, K.; Pareek, M.; Parfrey, H.; Pariante, C.; Parker, S.; Parkes, M.; Parmar, J.; Patale, S.; Patel, B.; Patel, M.; Patel, S.; Pattenadk, D.; Pavlides, M.; Payne, S.; Pearce, L.; Pearl, J.E.; Peckham, D.; Pendlebury, J.; Peng, Y.; Pennington, C.; Peralta, I.; Perkins, E.; Peterkin, Z.; Peto, T.; Petousi, N.; Petrie, J.; Phipps, J.; Pimm, J.; Piper, Hanley, K.; Pius, R.; Plant, H.; Plein, S.; Plekhanova, T.; Plowright, M.; Polgar, O.; Poll, L.; Porter, J.; Portukhay, S.; Powell, N.; Prabhu, A.; Pratt, J.; Price, A.; Price, C.; Price, C.; Price, D.; Price, L.; Price, L.; Prickett, A.; Propescu, J.; Pugmire, S.; Quaid, S.; Quigley, J.; Qureshi, H.; Qureshi, I.N.; Radhakrishnan, K.; Ralser, M.; Ramos, A.; Ramos, H.; Rangeley, J.; Rangelov, B.; Ratcliffe, L.; Ravencroft, P.; Reddington, A.; Reddy, R.; Redfearn, H.; Redwood, D.; Reed, A.; Rees, M.; Rees, T.; Regan, K.; Reynolds, W.; Ribeiro, C.; Richards, A.; Richardson, E.; Rivera Ortega, P.; Roberts, K.; Robertson, E.; Robinson, E.; Robinson, L.; Roche, L.; Roddis, C.; Rodger, J.; Ross, A.; Ross, G.; Rossdale, J.; Rostron, A.; Rowe, A.; Rowland, A.; Rowland, J.; Roy, K.; Roy, M.; Rudan, I.; Russell, R.; Russell, E.; Saalmink, G.; Sabit, R.; Sage, E.K.; Samakomva, T.; Samani, N.; Sampson, C.; Samuel, K.; Samuel, R.; Sanderson, A.; Sapey, E.; Saralaya, D.; Sargant, J.; Sarginson, C.; Sass, T.; Sattar, N.; Saunders, K.; Saunders, P.; Saunders, L.C.; Savill, H.; Saxon, W.; Sayer, A.; Schronce, J.; Schwaeble, W.; Scott, K.; Selby, N.; Sewell, T.A.; Shah, K.; Shah, P.; Shankar Hari, M.; Sharma, M.; Sharpe, C.; Sharpe, M.; Shashaa, S.; Shaw, A.; Shaw, K.; Shaw, V.; Shelton, S.; Shenton, L.; Shevket, K.; Short, J.; Siddique, S.; Siddiqui, S.; Sidebottom, J.; Sigfrid, L.; Simons, G.; Simpson, J.; Simpson, N.; Singh, C.; Singh, S.; Sissons, D.; Skeemer, J.; Slack, K.; Smith, A.; Smith, D.; Smith, S.; Smith, J.; Smith, L.; Soares, M.; Solano, T.S.; Solly, R.; Solstice, A.R.; Soulsby, T.; Southern, D.; Sowter, D.; Spears, M.; Spencer, L.G.; Speranza, F.; Stadon, L.; Stanel, S.; Steele, N.; Steiner, M.; Stensel, D.; Stephens, G.; Stephenson, L.; Stern, M.; Stewart, I.; Stimpson, R.; Stockdale, S.; Stockley, J.; Stoker, W.; Stone, R.; Storrar, W.; Storrie, A.; Storton, K.; Stringer, E.; Strong Sheldrake, S.; Stroud, N.; Subbe, C.; Sudlow, C.L.; Suleiman, Z.; Summers, C.; Summersgill, C.; Sutherland, D.; Sykes, D.L.; Sykes, R.; Talbot, N.; Tan, A.L.; Tarusan, L.; Tavoukjian, V.; Taylor, A.; Taylor, C.; Taylor, J.; Te, A.; Tedd, H.; Tee, C.J.; Teixeira, J.; Tench, H.; Terry, S.; Thackray Nocera, S.; Thaivalappil, F.; Thamu, B.; Thickett, D.; Thomas, C.; Thomas, S.; Thomas, A.K.; Thomas Woods, T.; Thompson, T.; Thompson, A A R.; Thornton, T.; Tilley, J.; Tinker, N.; Tiongson, G.F.; Tobin, M.; Tomlinson, J.; Tong, C.; Touyz, R.; Tripp, K.A.; Tunnicliffe, E.; Turnbull, A.; Turner, E.; Turner, S.; Turner, V.; Turner, K.; Turney, S.; Turtle, L.; Turton, H.; Ugoji, J.; Ugwuoke, R.; Upthegrove, R.; Valabhji, J.; Ventura, M.; Vere, J.; Vickers, C.; Vinson, B.; Wade, E.; Wade, P.; Wainwright, T.; Wajero, L.O.; Walder, S.; Walker, S.; Walker, S.; Wall, E.; Wallis, T.; Walmsley, S.; Walsh, J.A.; Walsh, S.; Warburton, L.; Ward, T.J.C.; Warwick, K.; Wassall, H.; Waterson, S.; Watson, E.; Watson, L.; Watson, J.; Welch, C.; Welch, H.; Welsh, B.; Wessely, S.; West, S.; Weston, H.; Wheeler, H.; White, S.; Whitehead, V.; Whitney, J.; Whittaker, S.; Whittam, B.; Whitworth, V.; Wight, A.; Wild, J.; Wilkins, M.; Wilkinson, D.; Williams, N.; Williams, N.; Williams, J.; Williams Howard, S.A.; Willicombe, M.; Willis, G.; Willoughby, J.; Wilson, A.; Wilson, D.; Wilson, I.; Window, N.; Witham, M.; Wolf Roberts, R.; Wood, C.; Woodhead, F.; Woods, J.; Wormleighton, J.; Worsley, J.; Wraith, D.; Wrey, Brown, C.; Wright, C.; Wright, L.; Wright, S.; Wyles, J.; Wynter, I.; Xu, M.; Yasmin, N.; Yasmin, S.; Yates, T.; Yip, K.P.; Young, B.; Young, S.; Young, A.; Yousuf, A.J.; Zawia, A.; Zeidan, L.; Zhao, B.; Zongo, O. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir. Med., 2022, 10(8), 761-775.
[http://dx.doi.org/10.1016/S2213-2600(22)00127-8] [PMID: 35472304]
[120]
Bridger Staatz, C.; Bann, D.; Ploubidis, G.B.; Goodman, A.; Silverwood, R.J. Age of first overweight and obesity, COVID-19 and long COVID in two british birth cohorts. J. Epidemiol. Glob. Health, 2023, 13(1), 140-153.
[http://dx.doi.org/10.1007/s44197-023-00093-5] [PMID: 36811824]
[121]
Huerne, K.; Filion, K.B.; Grad, R.; Ernst, P.; Gershon, A.S.; Eisenberg, M.J. Epidemiological and clinical perspectives of long COVID syndrome. Am. J. Med. Open, 2023, 9, 100033.
[http://dx.doi.org/10.1016/j.ajmo.2023.100033] [PMID: 36685609]
[122]
Antonelli, M.; Pujol, J.C.; Spector, T.D.; Ourselin, S.; Steves, C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet, 2022, 399(10343), 2263-2264.
[http://dx.doi.org/10.1016/S0140-6736(22)00941-2] [PMID: 35717982]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy